TIGIT and neoplasm: The importance of the Fc domain of anti-TIGIT mAb is emphasized by the findings that anti-TIGIT mAb with Fc devoid of effector functions, which was intended to solely block TIGIT binding to its ligands, fails to exert any of anti-tumor efficacies in preclinical models [36,73,74].